ASCENDIS PHARMA A/S - ADR (ASND) Stock Income Statement
NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 368.70M | 363.64M | 266.72M | 51.17M | 7.78M | |||
| Cost Of Goods | 54.21M | 44.26M | 44.40M | 12.14M | 3.52M | |||
| Gross Profit | 314.50M | 319.38M | 222.32M | 39.04M | 4.26M | |||
| Operating Expenses | 640.82M | 598.15M | 670.03M | 600.85M | 456.05M | |||
| Research and Development | 311.49M | 299.55M | 395.32M | 368.73M | 285.77M | |||
| Selling, General, and Administrative Expenses | 314.39M | 284.08M | 258.30M | 215.85M | 155.59M | |||
| Operating Income | -326.32M | -278.76M | -447.71M | -561.81M | -451.79M | |||
| Interest Income/Expense | -4.45M | -67.33M | -18.60M | -11.68M | 67.85M | |||
| Other Income/Expense | N/A | -27.15M | 0.00 | -4.32M | N/A | |||
| Non Recurring Items | N/A | 0.00 | -7.83M | N/A | N/A | |||
| Income Before Taxes | -338.28M | -373.24M | -474.14M | -577.82M | -383.94M | |||
| Income Tax | 3.40M | 4.84M | 7.30M | 5.38M | -370.00K | |||
| Net Income | -341.67M | -378.08M | -481.45M | -583.19M | -383.58M | |||
| EBITDA | -308.54M | -261.05M | -428.80M | -543.86M | -436.39M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -5.81 | -6.48 | -8.49 | -10.32 | -6.94 | |||
| Non GAAP EPS | -5.85 | -6.57 | -8.56 | -10.40 | -7.01 | |||
| Statistics | ||||||||
| Gross Profit Margin | 85.30% | 87.83% | 83.36% | 76.29% | 54.76% | |||
| Profit Margin | -92.67% | -103.97% | -180.51% | -1139.71% | -4930.33% | |||
| Operating Profit Margin | -88.51% | -76.66% | -167.86% | -1097.93% | -5807.07% | |||
All data in EUR